Expression data from cardiac stem cells (CSCs) with or without MSC-exosomes treatment

Cardiac resident c-kit+ cells aroused much interest among the cardiologists at the beginning of the century. These cells are selfrenewing, clonogenic, and multipotent and possess the potential to differentiate into all cardiovascular lineages. However, one of the critical problems faced by c-kit+ cells is the poor engraftment and survival after transplantation. Therefore, researchers are focusing on developing next generation CSC products that will enhance the engraftment, survival, and regenerative capabilities of these cells. Considering this, we made a proposal that cardiac stem cells preconditioned with exosomes derived from bone marrow mesenchymal stem cells could survive and function better in a myocardial infarction model.本世纪初，心脏驻留型c-kit+细胞便引发了心血管领域研究者的广泛关注。这类细胞具备自我更新、克隆形成及多向分化潜能，可分化为所有心血管谱系细胞。然而，c-kit+细胞移植后存在定植效率低下、存活率不佳这一关键难题。为此，研究者正致力于开发新一代心脏干细胞（Cardiac Stem Cell, CSC）制剂，以提升这类细胞的定植能力、存活率及再生效能。基于此背景，本研究提出假说：经骨髓间充质干细胞（bone marrow mesenchymal stem cells）衍生外泌体（exosomes）预处理的心脏干细胞，可在心肌梗死模型（myocardial infarction model）中展现更优的存活状态与功能表现。